CRISPR Therapeutics
CRSP
440 hedge funds and large institutions have $4.68B invested in CRISPR Therapeutics in 2025 Q3 according to their latest regulatory filings, with 73 funds opening new positions, 148 increasing their positions, 118 reducing their positions, and 58 closing their positions.
33% more capital invested
Capital invested by funds: $3.52B → $4.68B (+$1.16B)
26% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 58
25% more repeat investments, than reductions
Existing positions increased: 148 | Existing positions reduced: 118
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
13% more call options, than puts
Call options by funds: $307M | Put options by funds: $271M
2% more funds holding
Funds holding: 433 → 440 (+7)
4.36% less ownership
Funds ownership: 83.79% → 79.43% (-4.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$127M |
| 2 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
+$56.8M |
| 3 |
BlackRock
New York
|
+$56.5M |
| 4 |
Morgan Stanley
New York
|
+$50.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$42.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$46.9M |
| 2 |
Two Sigma Advisers
New York
|
-$44.3M |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$41.7M |
| 4 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$30.4M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$29M |
CRSP Hedge Fund Activity: Q3 2025 in Review
440 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q3 2025, worth a combined $4.68B — up 33% from $3.52B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new CRSP positions and 58 closed out — a net gain of 15 holders — while 148 added to existing stakes and 118 trimmed.
The largest buyer was Orbis Allan Gray, adding an estimated $127M. The largest seller was UBS AM, exiting entirely with an estimated $46.9M sold.
- 440 institutional investors held CRISPR Therapeutics (CRSP) as of Q3 2025, up from 433 in Q2 2025.
- Funds reported $4.68B of CRISPR Therapeutics stock for Q3 2025, up 33% quarter-over-quarter.
- 73 funds opened new CRISPR Therapeutics positions in Q3 2025 and 58 closed out, a net change of +15 holders.
- The largest CRISPR Therapeutics buyer in Q3 2025 was Orbis Allan Gray, an estimated $127M added.
- The largest CRISPR Therapeutics seller in Q3 2025 was UBS AM, an estimated $46.9M sold.
Based on aggregated 13F filings for Q3 2025.